The U.S. Centers for Medicare & Medicaid Services (CMS) has approved a new technology add-on payment (NTAP) for Stemline Therapeutics’ (STML+2.6%) ELZONRIS (tagraxofusp-erzs) for the treatment of patients at least two years old with a rare type of leukemia called blastic plasmacytoid dendritic cell neoplasm (BPDCN). The additional payment will go into effect October 1.
The specific amount of the NTAP is not provided, but it will be paid over and above the usual DRG-based amount.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.